Dendreon: Provenge's Shortcomings Have the Shorts Coming - Seeking Alpha

Dendreon: Provenge's Shortcomings Have the Shorts Coming - Seeking Alpha: "Ishmiel Kapur submits: Perhaps one of the fastest stocks being shorted this past week and this coming week will be the one and only Dendreon Corporation (DNDN). That's right, this was the one that soared a few hundred percent a few weeks back as FDA advisors recommended the approval of their prostate cancer drug. You see how I emphasized 'recommended'? That's because the actual FDA regulators haven't actually given the final approval. And now there have been plenty of signs pointing to the possibility that they'll get a big red stamp on their application papers stating either rejected, turned-down, or even dismissed."